These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18413374)

  • 21. Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.
    Kwong A; Wong CH; Suen DT; Co M; Kurian AW; West DW; Ford JM
    World J Surg; 2012 Apr; 36(4):702-13. PubMed ID: 22290208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of BRCA1/2 mutation prediction models in Asian Americans.
    Kurian AW; Gong GD; Chun NM; Mills MA; Staton AD; Kingham KE; Crawford BB; Lee R; Chan S; Donlon SS; Ridge Y; Panabaker K; West DW; Whittemore AS; Ford JM
    J Clin Oncol; 2008 Oct; 26(29):4752-8. PubMed ID: 18779604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of models to predict BRCA germline mutations.
    Kang HH; Williams R; Leary J; ; Ringland C; Kirk J; Ward R
    Br J Cancer; 2006 Oct; 95(7):914-20. PubMed ID: 17016486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
    J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
    Evans DG; Eccles DM; Rahman N; Young K; Bulman M; Amir E; Shenton A; Howell A; Lalloo F
    J Med Genet; 2004 Jun; 41(6):474-80. PubMed ID: 15173236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
    Kang E; Park SK; Yang JJ; Park B; Lee MH; Lee JW; Suh YJ; Lee JE; Kim HA; Oh SJ; Kim SW;
    Breast Cancer Res Treat; 2012 Aug; 134(3):1189-97. PubMed ID: 22438049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
    Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D
    J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer.
    Rybchenko LA; Bychkova AM; Skyban GV; Klymenko SV
    Probl Radiac Med Radiobiol; 2013; (18):253-60. PubMed ID: 25191729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.
    van Harssel JJ; van Roozendaal CE; Detisch Y; Brandão RD; Paulussen AD; Zeegers M; Blok MJ; Gómez García EB
    Fam Cancer; 2010 Jun; 9(2):193-201. PubMed ID: 19949876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
    Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
    Bonaïti B; Alarcon F; Andrieu N; Bonadona V; Dondon MG; Pennec S; Stoppa-Lyonnet D; Bonaïti-Pellié C; Perdry H
    J Med Genet; 2014 Feb; 51(2):114-21. PubMed ID: 24343917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
    Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
    Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
    Rao NY; Hu Z; Li WF; Huang J; Ma ZL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Feb; 113(3):467-77. PubMed ID: 18343994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.
    Daniels MS; Babb SA; King RH; Urbauer DL; Batte BA; Brandt AC; Amos CI; Buchanan AH; Mutch DG; Lu KH
    J Clin Oncol; 2014 Apr; 32(12):1249-55. PubMed ID: 24638001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
    Kurian AW; Gong GD; John EM; Miron A; Felberg A; Phipps AI; West DW; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1084-91. PubMed ID: 19336551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
    Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
    Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
    Antoniou AC; Pharoah PP; Smith P; Easton DF
    Br J Cancer; 2004 Oct; 91(8):1580-90. PubMed ID: 15381934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
    Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
    Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.